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Abstract
Von Hippel-Lindau syndrome (VHL) is an autosomal dominant disease caused by a genetic aberration of the tumor suppressor gene VHL 
and characterized by multi-organ tumors. The most common neoplasm is retinal or cerebral hemangioblastoma, although spinal hemangio-
blastomas, Renal Clear Cell Carcinoma (RCCC), pheochromocytomas (Pheo), paragangliomas, Pancreatic Neuroendocrine Tumors (PNETs), 
cystadenomas of the epididymis, and tumors of the lymphatic sac can also be found. Neurological complications from retinal or CNS hemangio-
blastoma and metastases of RCCC are the most common causes of death. There is a strong association between pheochromocytoma and VHL 
syndrome, and pheochromocytoma is often a classic manifestation of the syndrome. RCCCs are often incidental and identified during other 
tests. Between 35 and 70% of patients with VHL have pancreatic cysts. These can manifest as simple cysts, serous cysto-adenomas, or PNETs 
with a risk of malignant degeneration or metastasis of no more than 8%. The objective of this retrospective study is to analyze abdominal man-
ifestations of VHL from a surgical point of view.
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In 1894, Collins reported a bilateral incidence of retinal 
hemangioblastomas in twins, which were referred to as nevi, 
whereas the German ophthalmologist Von Hippel discussed 
cases of retinal angiomatosis. In 1926, the Sweden pathol-
ogist Lindau identified an association between the retinal 
angiomatosis and the hemangioblastomas in the cerebellum. 
In the 1960s, the disease was termed Von Hippel-Lindau 
disease (VHL) (1–3). From 1960 to 1990, VHL disease was 
diagnosed on the basis of clinical signs and symptoms. How-
ever, in 1988, Seizinger et al. (4) identified an alteration on the 
short arm of chromosome 3 (3p25–3p26). In 1993, it became 
possible to isolate the gene responsible for the disease, which 
was named the VHL gene (4,5). VHL is an autosomal dom-
inant disease caused by genetic aberration of the tumor 
suppressor gene. It is characterized by multi-organ tumors 
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of the central nervous system, kidney, pancreas, and adre-
nal and reproductive organs. The most common neoplasm 
is retinalor cerebral hemangioblastoma, although spinal 
hemangioblastomas, Renal Clear Cell Carcinoma (RCCC), 
pheochromocytomas (Pheo), paragangliomas, Pancreatic 
Neuroendocrine Tumors (PNETs), cystadenomas of the epi-
didymis, and tumors of the lymphatic sac can also be found. 
Life expectancy is approximately 60 years for men and 50 
years for women. VHL related mortality is due to compli-
cations from CNS and RCCC tumors (6–8). The onset of 
symptoms appear in the second decade of life; it therefore 
develops in childhood or adolescence. It has an incidence 
rate of 3:100,000 people per year. The VHL gene is located 
on chromosome 3p25, which consists of three exons for the 
pVHL gene (a tumor suppressor protein). When the pVHL 
is not produced due to mutations in the VHL gene (mainly 
deletions), angiogenesis and uncontrolled cell proliferation 
are promoted. Therefore, the pVHL mutations seriously 
increase the risk of tumor growth in the organs indicated 
(8–10). Approximately 70% of the VHL cases are hemangio-
blastomas and clear renal cell carcinoma (RCC). The latter is 
often the main factor affecting prognosis, with kidney cancer 
being the most common cause of death. For these patients, 
there is an association between VHL and (i) PNETs with an 
incidence ranging from 5 to 18% and (ii) (Pheo) that occur in 
up to 20% of the patients (11–15).The objective of this ret-
rospective study is to analyze abdominal manifestations of 
VHL from a surgical point of view.
Materials and Methods
We conducted a retrospective evaluation of PubMed arti-
cles. A total of 6537 results appeared when searching for 
VHL. The pool of results were then massively reduced 
by only selecting articles from 2000 to 2021. A combina-
tion of medical subject heading (MeSH) terms and key-
words were used for the search. The inclusion criteria were 
“Von  Hippel-Lindau; Pheocromocytoma; Clear Cell Renal 
 Cancer; PNET.” The primary outcome measure was “VHL 
surgical treatment.” Two authors analyzed the articles. The 
methodologies applied in the articles were randomized con-
trolled trials (RCTs), cohort studies, case–control studies, 
randomized studies, and prospective and retrospective stud-
ies. Studies in all languages were included. We excluded case 
reports and articles not focused on surgical management.
Results
In a retrospective study, Zwolak et al. (16) found that in the 
general population, PNETs in VHL have an estimated inci-
dence of approximately 5–18%. However, PNETs comprise 
only 5% of pancreatic cancers and the association between 
PNETs and VHL is less than 0.5%. Distant metastases are 
found in 60–90% of sporadic PNETs,  whereas in VHL the 
incidence of metastases is estimated at 11–20%. Sporadic 
non-secreting neuroendocrine tumors of the pancreas should 
be removed when they are greater than 20 mm in diame-
ter. Smaller tumors can be observed if  they do not exhibit 
radiological or histopathological features of malignancy. Hes 
et al. (17) conducted a genetic analysis of VHL, targeting the 
formation of pheochromocytomas. They highlighted 3 types 
of VHL associated with 3 subtypes classification: Type  1, 
not from pheochromocytomas and mutations in patients 
with this type of VHL; Type 2, which has the appearance 
of pheochromocytomas and can be further subdivided into 
3 subtypes: low (type 2A), and high (type 2B) risk of RCC, 
type 2C families with pheochromocytoma only, type 3 Chu-
vash polycythemia.. In an extensive review of the relevant 
literature, Varshney et al. (18) found multiple bilateral renal 
cysts in 50–70% of patients with VHL, and RCC in 30% of 
patients with VHL. In the third or fourth decade of life, renal 
cysts are often multiple but asymptomatic and without renal 
insufficiency or with RCC. They noted that RCC, which is 
the main cause of mortality in this group of patients, has an 
incidence of 70% after the age of 60. Pheochromocytomas 
occur in up to 20% of VHL patients in the second decade 
of life; these are bilateral or multifocal and secrete catechol-
amines. The treatment of choice for pheochromocytomas is 
surgical resection using laparoscopic approaches. Approx-
imately 35–70% of the patients with VHL have pancreatic 
cysts. Baghai et al. (19), in their retrospective study at Mayo 
Clinic Hospital, analyzed 109 patients affected by VHL. They 
found 46% of RCCC, 76% of cerebral or cerebellar heman-
gioblastoma, 63% of retinal angioma, 16% of pheocromocy-
toma, 3% of paraganglioma, and 43% of pancreatic lesions. 
After open or laparoscopic adrenalectomy for Pheo, mean 
size was between 1.5 and 6.5 cm with no invasive tumors or 
metastases (16 patients), and 50% of these had concurrent 
procedure for pancreatic cancer or renal cancer (Table 1).
Discussion
VHL disease is an autosomal, dominant hereditary tumor 
syndrome with an estimated prevalence of 2–3 per 100,000 
people. It predisposes people to hemangioblastoma in the ret-
ina, cerebellum, and spine; renal cell carcinoma, pheochro-
mocytoma; islet cell tumors of the pancreas; endolymphatic 
sac tumors; and cysts in the pancreas and epididymis. Neuro-
logical complications from retinal or CNS hemangioblastoma 
and metastases of RCC are the most common causes of death 
(5,8,20). The current clinical classification of VHL comprises 
three types, 1-2-3. Of these, type 2 contains three subtypes. 
Type 1 is characterized by a high risk of renal cell carci-
noma. Types 2a and 2b are characterized by a high risk of 
both renal cell carcinoma and pheochromocytoma, whereas 
type 2c is characterized by a high risk of pheochromocytoma. 
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Type 3 is characterized by a risk of Chuvash polycythemia 
(8–10) (Table 2). Currently, there are no guidelines for the 
management of hemangioblastoma. Patients with heman-
gioblastoma inoperable for local dimensions or who are not 
fit because they are at a high risk of operative complications 
can be managed with conventional fractional radiotherapy or 
stereotaxic radiosurgery. Small hemangioblastomas appear 
to benefit from conservative treatment with radiological fol-
low-up. Therefore, only symptomatic hemangioblastomas 
should be managed operatively (Weil). Preoperative emboli-
zation of hemangioblastomas also appears to be acceptable 
and safe; this procedure reduces blood loss during surgery 
and the incidence of postoperative complications (21).There 
is a strong association between pheochromocytoma and 
VHL syndrome, and pheochromocytoma is often a classic 
manifestation of the latter. Pheochromocytoma occurs in up 
to 20% of patients with VHL in the second decade of life and 
can be bilateral or multifocal. It typically develops in young 
adults and its location may be adrenal or extra-adrenal. 
Often, they may exhibit a low secretory activity while classic 
symptoms (such as tachycardia, sweating, tachypnea, head-
ache, angina, and palpitations) may be absent. The treatment 
of choice for pheochromocytomas is surgical resection using 
either a laparoscopic transperitoneal, extraperitoneal, or 
robotic laparoscopic approach (22,23).This approach yields 
excellent results with no recurrence (24,25). RCCs are often 
incidental and identified during other tests. Partial nephrec-
tomy is recommended for 3 cm tumors. Nephro-sparing on 
lesions of 3 cm or greater result in 10 year cancer survival 
rates of up to 81%. Percutaneous and laparoscopic radiof-
requency ablation therapy is effective in the treatment of 
smaller tumors (<3 cm) (26,27). The pancreatic lesions found 
in VHL disease are a heterogeneous group comprising the 
following: PNETs, simple cysts, serous cystadenomas, and 
mixed neuroendocrine neoplasms. Cysts are the most com-
mon and have been found in 17–72% of the cases (28–30). 
Pancreatic resection is performed only for PNETs measuring 
at least 2 cm in size or any size if  they have malignant char-
acteristics. Small tumors can be observed if  no radiological 
or histopathological features of malignancy are exhibited. If  
a pancreatic NET is small, enucleation is performed. A dis-
tal pancreatectomy is used to treat PNETs present in the tail 
and body of the pancreas. Surgical options involve remov-
ing only the tail of the pancreas or performing a pancreatic 
splenectomy via open surgery or laparoscopy or robotics. A 
Whipple procedure is used to treat pancreatic NETs found in 
the head of the pancreas. A central pancreatectomy is used 
to treat small, low grade tumors (31,32). Blansfield et al. (13) 
identified three main factors that can determine the risk of 
metastasis: tumor size, exon 3 mutation, and mean doubling 
time. There is an apparent 12% association between neuro-
endocrine tumors of the pancreas and pheochromocytomas 
in patients with VHL disease (33). Approximately 35–70% of 
patients with VHL have pancreatic cysts. These can manifest 
as simple cysts, serous cysto-adenomas, or PNETs with a risk 
of malignant degeneration or metastasis of no more than 8%. 
The resection criteria are given by a major tumor of 3 cm or 
a pathogenic variant in exon 3 and tumor with a growth rate 
doubling in fewer than 500 days. Because these characteristics 
increase the risk of metastasis, enucleation, Whipple, or dis-
tal pancreatectomy is indicated depending on the site (13,34, 
35). In recent years new medical therapies targeting the VHL/
HIF axis have been investigated, with some of them being 
used in clinical trials. The most commonly utilized are tyro-
sine kinase inhibitors (TKIs), which can decrease angiogene-
sis by blocking the VEGF pathway. Several TKIs including 
sunitinib, cabozantinib, axitinib, lenvatinib, and pazopanib 
are currently being evaluated in phase II clinical trials. These 
therapies work by inhibiting cancer cell proliferation, metas-
tasis, and the development of therapeutic resistance by sup-
pressing tyrosine kinase receptors (36). Recently, studies were 
investigated on belzutifan, development code: MK-6482, 
Table 2: Type of VHL, clinical findings, gene mutations, and notes.
Type of VHL Clinical findings Gene Notes




Decreased risk for Pheo
Type 2
Type 2A CNS and retinal HB Pheo Missense mutation Low risk for RCC
Type 2B RCCC, Retinal HB, CNS HB,pancreatic cyst, and 
neuroendocrinetumors, Pheo
– High risk of RCC
Type 2C Pheo – High risk of Pheo
Type 3 Chuvash polycythemia. –
CNS: central nervous system; HB: hemangioblastoma; RCCC: Renal Clear Cell Carcinoma; Pheo: Pheocromocytoma.
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which is a hypoxia-inducible factor-2α (HIF-2α) inhibitor 
for the treatment of adult patients with Hippel-Lindau syn-
drome. This agent is not FDA approved in US and had a 83% 
response rate in PNETs (37–39).
Conclusions
VHL syndrome exhibits a wide range of signs and symptoms 
and is often difficult to diagnose. It is a multisystem tumor 
syndrome with common manifestations affecting the CNS 
and various visceral organs. VHL patients often require mul-
tidisciplinary treatment, including genetic counseling and 
personnel such as surgeons, radiologists, pathologists, and 
oncologists. Early identification of mutations leads to early 
intervention and reduces rates of morbidity and mortality. 
Although the use of surgery to treat hemangioblastomas 
yields promising results, RCC appears to benefit consider-
ably from a combination of surgery and the use of targeted 
therapies such as VEGF. The future promises an even greater 
understanding of the genetic structure of the disease, facili-
tating its treatment with increasingly specific drugs.
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